Revolution Medicines surges 38% as pancreatic cancer drug shows breakthrough

Shares of Revolution Medicines surged sharply on Monday after the company reported positive results from a late-stage trial of its experimental pancreatic cancer drug, raising hopes for a potential breakthrough in one of the deadliest forms of the disease. The stock climbed 38% after the opening bell, extending gains to 69% since the start of the year.